The Greenville, South Carolina, CCOP has long-term objectives that include: 1) Re-establishing a unified and cooperative research effort with the Greenville Hospital System (GHS). 2) Solidification of cancer prevention and control outreach and communication throughput throughout the Upstate of South Carolina. 3) Increasing participation in ancillary studies associated with the science of hematologic malignancies. 4) Expansion of our CCOP capabilities associated with potentially innovative surgical techniques offered by our newly developed surgical oncology expertise. 5) Further development of a sustaining CCOP governance with improvement in quality control. 6) Participation in NCI-supported stem cell transplant research. While the initial years of our existence have been marked by political turmoil between the grantee and GHS, there are recent developments that give us cause to believe that a unified effort is now possible much to the gain of this community and it patients. We will work diligently to make certain that the momentum is maintained. This degree of utility and cooperation between the CCOP and the two major hospitals in this county will most certainly translate into an improved cancer control and prevention effort. As this area has grown, so too has the medical expertise and diversity of capabilities and diversity of capabilities. Studies that had before been beyond our research are now feasible. As we have matured, we feel that we can move beyond Phase III trials and offer this population something more. The growing pains of the last five years of our existence have taken their tool. Our major prioritized effort was that of patient accrual and timely, accurate data submission. We are now hopeful, as we have reached a degree of maturity and stability, that we will fine-tune the governance of the organization to include the development of a quality assurance program inclusive of quality indicators and parameters we must strive to achieve.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA067663-08
Application #
6512884
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Parnes, Howard L
Project Start
1995-09-25
Project End
2006-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
8
Fiscal Year
2002
Total Cost
$553,200
Indirect Cost
Name
Oncology & Hematology Associates of SC
Department
Type
DUNS #
City
Greenville
State
SC
Country
United States
Zip Code
29605
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 95 publications